Literature DB >> 16094559

Minimum inhibitory concentrations of tulathromycin against respiratory bacterial pathogens isolated from clinical cases in European cattle and swine and variability arising from changes in in vitro methodology.

Kevin S Godinho1, Sue G Keane, Ian A Nanjiani, Hafid A Benchaoui, Simon J Sunderland, M Anne Jones, Andrew J Weatherley, Thomas D Gootz, Tim G Rowan.   

Abstract

The in vitro activity of tulathromycin was evaluated against common bovine and porcine respiratory pathogens collected from outbreaks of clinical disease across eight European countries from 1998 to 2001. Minimum inhibitory concentrations (MICs) for one isolate of each bacterial species from each outbreak were determined using a broth microdilution technique. The lowest concentrations inhibiting the growth of 90% of isolates (MIC90) for tulathromycin were 2 microg/ml for Mannheimia (Pasteurella) haemolytica, 1 microg/ml for Pasteurella multocida (bovine), and 2 microg/ml for Pasteurella multocida (porcine) and ranged from 0.5 to 4 microg/ml for Histophilus somni (Haemophilus somnus) and from 4 to 16 microg/ml for Actinobacillus pleuropneumoniae. Isolates were retested in the presence of serum. The activity of tulathromycin against fastidious organisms was affected by culture conditions, and MICs were reduced in the presence of serum.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16094559

Source DB:  PubMed          Journal:  Vet Ther        ISSN: 1528-3593


  5 in total

1.  An evaluation of the relative efficacy of tulathromycin for the treatment of undifferentiated fever in feedlot calves in Nebraska.

Authors:  Oliver C Schunicht; Calvin W Booker; P Timothy Guichon; G Kee Jim; Brian K Wildman; Tom J Pittman; Tye Perrett
Journal:  Can Vet J       Date:  2007-06       Impact factor: 1.008

2.  Evidence for Establishing the Clinical Breakpoint of Cefquinome against Haemophilus Parasuis in China.

Authors:  Kun Mi; Da Sun; Mei Li; Haihong Hao; Kaixiang Zhou; Zhenli Liu; Zonghui Yuan; Lingli Huang
Journal:  Pathogens       Date:  2021-01-22

3.  Pharmacokinetic/Pharmacodynamic Relationships of Tulathromycin Against Actinobacillus pleuropneumoniae in a Porcine Tissue Cage Infection Model.

Authors:  Lihua Yao; Lan Yang; Yuzhou Ling; Yanzhe Wei; Xiangguang Shen; Huanzhong Ding
Journal:  Front Vet Sci       Date:  2022-03-28

4.  The pharmacokinetic-pharmacodynamic modeling and cut-off values of tildipirosin against Haemophilus parasuis.

Authors:  Zhixin Lei; Qianying Liu; Bing Yang; Saeed Ahmed; Jiyue Cao; Qigai He
Journal:  Oncotarget       Date:  2017-12-07

5.  Pharmacokinetic/pharmacodynamic (PK/PD) evaluation of tulathromycin against Haemophilus parasuis in an experimental neutropenic guinea pig model.

Authors:  Yongda Zhao; Li-Li Guo; Binghu Fang; Baotao Liu
Journal:  PLoS One       Date:  2018-12-31       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.